Stevens Capital Management LP lessened its stake in shares of Agilent Technologies Inc (NYSE:A) by 66.0% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 14,011 shares of the medical research company’s stock after selling 27,156 shares during the quarter. Stevens Capital Management LP’s holdings in Agilent Technologies were worth $988,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also bought and sold shares of A. Fiera Capital Corp acquired a new stake in shares of Agilent Technologies in the 2nd quarter worth about $565,000. Virginia Retirement Systems ET AL acquired a new stake in shares of Agilent Technologies in the 2nd quarter worth about $359,000. Commonwealth of Pennsylvania Public School Empls Retrmt SYS acquired a new stake in shares of Agilent Technologies in the 2nd quarter worth about $2,071,000. Sei Investments Co. increased its stake in Agilent Technologies by 42.3% in the 2nd quarter. Sei Investments Co. now owns 136,141 shares of the medical research company’s stock valued at $8,419,000 after buying an additional 40,462 shares during the last quarter. Finally, Engineers Gate Manager LP purchased a new stake in Agilent Technologies in the 2nd quarter valued at about $642,000.
Several research firms have commented on A. Morgan Stanley increased their price objective on shares of Agilent Technologies from $84.00 to $86.00 and gave the company an “overweight” rating in a research note on Wednesday, October 10th. ValuEngine upgraded shares of Agilent Technologies from a “hold” rating to a “buy” rating in a research note on Thursday, September 13th. Goldman Sachs Group reiterated a “buy” rating and issued a $82.00 price objective (up previously from $77.00) on shares of Agilent Technologies in a research note on Tuesday, September 18th. Zacks Investment Research lowered shares of Agilent Technologies from a “buy” rating to a “hold” rating in a research note on Tuesday, October 16th. Finally, Cleveland Research lowered shares of Agilent Technologies from a “buy” rating to a “neutral” rating in a research note on Monday, November 12th. Two analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $78.75.
In related news, CEO Michael R. Mcmullen sold 15,923 shares of the firm’s stock in a transaction that occurred on Monday, December 3rd. The shares were sold at an average price of $73.20, for a total value of $1,165,563.60. Following the completion of the transaction, the chief executive officer now directly owns 492,546 shares of the company’s stock, valued at approximately $36,054,367.20. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Dominique Grau sold 8,902 shares of the firm’s stock in a transaction that occurred on Monday, December 3rd. The stock was sold at an average price of $74.00, for a total transaction of $658,748.00. Following the completion of the transaction, the insider now directly owns 103,387 shares of the company’s stock, valued at $7,650,638. The disclosure for this sale can be found here. Insiders have sold a total of 34,683 shares of company stock valued at $2,499,491 over the last three months.
Agilent Technologies stock opened at $71.91 on Friday. Agilent Technologies Inc has a twelve month low of $60.42 and a twelve month high of $75.11. The company has a market cap of $23.24 billion, a PE ratio of 25.77, a P/E/G ratio of 2.04 and a beta of 1.36. The company has a quick ratio of 2.74, a current ratio of 3.29 and a debt-to-equity ratio of 0.39.
Agilent Technologies (NYSE:A) last released its earnings results on Monday, November 19th. The medical research company reported $0.81 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.74 by $0.07. Agilent Technologies had a net margin of 6.43% and a return on equity of 19.84%. The firm had revenue of $1.29 billion during the quarter, compared to the consensus estimate of $1.26 billion. During the same period in the prior year, the firm earned $0.67 EPS. The company’s revenue was up 8.8% compared to the same quarter last year. On average, equities analysts expect that Agilent Technologies Inc will post 3.04 EPS for the current fiscal year.
The business also recently announced a quarterly dividend, which will be paid on Wednesday, January 23rd. Stockholders of record on Monday, December 31st will be given a dividend of $0.164 per share. This is an increase from Agilent Technologies’s previous quarterly dividend of $0.15. This represents a $0.66 dividend on an annualized basis and a dividend yield of 0.91%. The ex-dividend date is Friday, December 28th. Agilent Technologies’s dividend payout ratio is currently 21.51%.
Agilent Technologies declared that its board has approved a stock buyback program on Monday, November 19th that allows the company to repurchase $1.75 billion in shares. This repurchase authorization allows the medical research company to purchase up to 8.8% of its shares through open market purchases. Shares repurchase programs are often an indication that the company’s management believes its shares are undervalued.
ILLEGAL ACTIVITY WARNING: “Agilent Technologies Inc (A) Shares Sold by Stevens Capital Management LP” was first reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this article on another site, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The correct version of this article can be viewed at https://www.dispatchtribunal.com/2018/12/07/agilent-technologies-inc-a-shares-sold-by-stevens-capital-management-lp.html.
Agilent Technologies Profile
Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. It operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; microfluidics based automated electrophoresis products; cell analysis plate based assays; laboratory software and informatics systems; laboratory automation; dissolution testing; vacuum pumps; and measurement technologies.
See Also: What is Considered a Good Return on Equity (ROE)?
Want to see what other hedge funds are holding A? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Agilent Technologies Inc (NYSE:A).
Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.